Skip to content

Immunofusion

Active Private limited companyfounded 2023active for 3 yearsRue Clément Ader 10, 6041 CharleroiKBO/BCE: BE 0804.563.629 subsidiary of

Lifetime

3 annual accounts with figures on one time axis
peak of -€13,585 in 2023
-€42,496▲ €30,174
lowest -€72,858 in 2024
-€42,606▲ €30,252
peak of -€10,585 in 2023
-€126,049▼ €42,606
€158,180▲ 79.3%
peak of 0 FTE in 2025
0 FTE 
Board2 names since 2023
2 directors and 1 other
Owners
consolidates
Documentsfilings and deeds
02-07-202629 days before the deadline
2025abbreviated format
Gross margin from -€72,670 to -€42,496Loss of €42,606Registered office moved to Gosselies 28-03Registered office moved from Beerse to Gosselies 28-03Equity from -€83,443 to -€126,049Debts from €88,204 to €158,180

Key points

from the 2025 annual accounts

Equity

-€126,049
202320242025

Debts exceed assets in financial year 2025.

Losses

-€129,049 in three years
-13,5852023-72,8582024-42,6062025

Every financial year from 2023 to 2025 closed with a loss. 2024 was the heaviest.

Debts

€158,180 492% of the balance sheet
After one year 2%Within one year 98%

Of this, €154,480 falls due within a year.

Board

1 joined · 1 left

Board changed. Latest change 29-09-2026 · 1 in office.

Position in the sector

-392.3%

Lower solvency than 95% of companies in research and development. Sector median 46.1% · 345 companies.

Turnover not published in the abbreviated or micro format

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 7,655 companies had the same profile as Immunofusion has now. Each dot stands for 20 companies, two years later.

84.6%
were still trading
5.8%
stopped another way
8.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • negative equity
  • a loss of 10% of the balance sheet or more

Another 0.7% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 7,655 companies, not a prediction for Immunofusion. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 01-05-2026
  • consolidatesannual accounts 2025
Board & ownership

Recent changes

resigns as director Director discharge: · General meeting of 20-07-2026 · Gazette deed
appointed as director General meeting of 21-04-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0804563629
Registered office moved to Gosselies The registered office moved to Rue Clément Ader 10, (South Charleroi BioPark Dev), 6041 Gosselies · Gazette deed
All 11 events

Comparable companies

same main activity, similar in size and age
Company
Immunofusion Charleroi €32,131 -€42,496 -392.3% 0
Belgium Volt Auderghem €41,754 -€31,037 -131.7% 0.5
HAPPY DIAB Binche €29,576 -€2,537 30.9% -
MANDIBLE GUIDE Woluwe-Saint-Pierre €64,270 -€14,605 -465.6% 1
GRAND MEDICAL (EUROPE) Niel €135,260 -€79,756 -1057.7% 0.4
Suomidoc Schoten €27,262 -€4,294 -4.5% -
1889 Consulting Forest €42,356 -€29,405 51.7% -

These companies have the same main activity as Immunofusion: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €27,300 and €135,000, founded between 2020 and 2024.

Official details

Source: KBO
Status
Active since 04-08-2023Normal situation
Registered office
36 active companies are registered at this address3 started in the 12 months before. Source: KBO register, as of 17 November 2026.
Activity
Other research and development on natural sciencesNACE 72109and 2 others
Establishment unit
2.349.352.0746041 Charleroi, registered on 04-08-2023
Financial year end
31 December
Peppol
Reachable since 28-10-2025
Company details

Annual accounts 2025

€32,131▲ 575%
Filing
Filed on 02-07-2026, 29 days before the end of the filing period
Financials

Insights on Immunofusion

Immunofusion files the abbreviated format. That format states no turnover. The gross margin fell from -€13,585 in 2023 to -€42,496 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Immunofusion

What is the company number of Immunofusion?
The company number of Immunofusion is 0804.563.629. The VAT number is the same number with BE in front: BE 0804.563.629.
Where is Immunofusion based?
The registered office is at Rue Clément Ader 10, 6041 Charleroi.Company details
What does Immunofusion do?
According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
What is the legal form of Immunofusion?
Immunofusion is a private limited company (BV).
When was Immunofusion founded?
Immunofusion was founded on 04-08-2023.
Is Immunofusion still active?
Yes, Immunofusion is an active enterprise in the KBO register.
What is the turnover of Immunofusion?
The annual accounts for financial year 2025 state no turnover. The abbreviated or micro format does not require it.Financials
Is Immunofusion profitable?
In financial year 2025, Immunofusion made a loss of €42,606.
Where can I find the annual accounts of Immunofusion?
Immunofusion filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Immunofusion due?
Immunofusion must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.